Report Detail
Europe Cancer Tissue Diagnostics Market to 2027 - Regional Analysis and Forecasts by Test Type (Immunohistochemical Tests and In Situ Hybridization Tests), and Country
- RnM3820307 |
- 08 November, 2019 |
- Global |
- 137 Pages |
- The Insight Partners |
- Biotechnology
Cancer tissue diagnostics market in Europe is expected to grow from US$ 512.73 Mn in the year 2018 and is expected to reach US$ 830.28 Mn by 2027 growing at a CAGR of 5.8% over the forecast period.
The growth of the market is driven by the factors such as increasing number of cancer cases and rising geriatric population. On the other hand, high cost of cancer diagnostics in some of the European countries is limiting the growth of market is likely to have a negative impact on the growth of the market in the coming years.
Personalize medicine is a relatively new approach; however it is expanding the field in the healthcare sector. It enables a medical practitioner to select treatment based on a patient's genetic profile. This helps to minimize harmful side effects as well as lead to successful results within a short duration.
Personalized medicines for cancer involves the study of individuals’ genetic make-up that leads to tumor growth. By studying the patient's genetic make-up, an oncologist may customize the treatment depending on the patient's genetic mutations. For instance, Mutations in ALK, KRAS, and EGFR lead to lung cancer. However, identifying the type of mutation in the lung cancer patient provides crucial information for the kind of treatment. Hence, personalized medicine allows the right treatment at the right time, which reduces the mortality rate. Due to these advantages of tailoring the treatment based on individual’s genetic profile, the personalized medicine approach is likely to be a prevalent trend for the cancer tissue diagnostics market.
In 2018, the immunohistochemical tests segment held a largest market share of the cancer tissue diagnostics market, by test type. This segment is expected to dominate the market in 2027 owing to the low cost of the procedure and higher acceptance of the method for diagnosis purpose. Additionally, the rising prevalence of cancer is a major factor for the growth of the diagnostic tests. The segment is also anticipated to witness the fastest growth rate during the forecast period, 2019 to 2027.
Some of the secondary sources used for validations and data mining in the Europe Cancer Tissue Diagnostics market includes Italian Association for Cancer Research (AIRC), Food and Drug Administration (FDA), National Health Services (NHS), World Health Organization (WHO), and others.
TABLE OF CONTENTS
1. Introduction
- 1.1 Scope Of The Study
- 1.2 The Insight Partners Research Report Guidance
2. Europe Cancer Tissue Diagnostics Market – Key Takeaways
3. Europe Cancer Tissue Diagnostics Market – Market Landscape
- 3.1 Overview
- 3.2 Market Segmentation
- 3.2.1 Europe Cancer Tissue Diagnostics Market – By Test Type
- 3.2.2 Europe Cancer Tissue Diagnostics Market – By Country
- 3.3 PEST Analysis
- 3.3.1 Europe – PEST Analysis
4. Europe Cancer Tissue Diagnostics Market - Key Market Dynamics
- 4.1 Key Market Drivers
- 4.1.1 Increasing Number of Cancer Cases
- 4.1.2 Increasing Geriatric Population
- 4.2 Key Market Restraint
- 4.2.1 High Cost of Cancer Diagnostics
- 4.3 Key Market Opportunities
- 4.3.1 Rising Healthcare Expenditure in Europe
- 4.4 Future Trends
- 4.4.1 Adoption of Personalized Medicine
- 4.5 Impact Analysis
5. Cancer Tissue Diagnostics Market – Europe Analysis
- 5.1 Europe Cancer Tissue Diagnostics Market Revenue Forecasts And Analysis
- 5.2 Performance Of Key Players
- 5.3 Positioning of Key Players
6. Europe Cancer Tissue Diagnostics Market Analysis –By Test Type
- 6.1 Overview
- 6.2 Europe Cancer Tissue Diagnostics Market, By Test Type, 2017 & 2027 (%)
- 6.3 Europe Cancer Tissue Diagnostics Market Revenue And Forecasts To 2027, By Test Type (US$ Mn)
- 6.4 Europe Immunohistochemical Tests Market
- 6.4.1 Overview
- 6.4.2 Europe Immunohistochemical Tests Market Revenue and Forecasts to 2027 (US$ Mn)
- 6.4.3 Breast Cancer Market
- 6.4.3.1 Overview
- 6.4.3.2 Breast Cancer Market Revenue and Forecast to 2027 (US$ Mn)
- 6.4.4 Colorectal Cancer Market
- 6.4.4.1 Overview
- 6.4.4.2 Colorectal Cancer Market Revenue and Forecast to 2027 (US$ Mn)
- 6.4.5 Prostate Cancer Market
- 6.4.5.1 Overview
- 6.4.5.2 Prostate Cancer Market Revenue and Forecast to 2027 (US$ Mn)
- 6.4.6 Stomach Cancer Market
- 6.4.6.1 Overview
- 6.4.6.2 Stomach Cancer Market Revenue and Forecast to 2027 (US$ Mn)
- 6.4.7 Others Market
- 6.4.7.1 Overview
- 6.4.7.2 Others Market Revenue and Forecast to 2027 (US$ Mn)
- 6.5 In Situ Hybridization Tests Market
- 6.5.1 Overview
- 6.5.2 In Situ Hybridization Tests Market Revenue and Forecast to 2027 (US$ Mn)
- 6.5.3 Breast Cancer Market
- 6.5.3.1 Overview
- 6.5.3.2 Breast Cancer Market Revenue and Forecast to 2027 (US$ Mn)
- 6.5.4 Lung Cancer Market
- 6.5.4.1 Overview
- 6.5.4.2 Lung Cancer Market Revenue and Forecast to 2027 (US$ Mn)
- 6.5.5 Bladder Cancer Market
- 6.5.5.1 Overview
- 6.5.5.2 Bladder Cancer Market Revenue and Forecast to 2027 (US$ Mn)
- 6.5.6 Others Market
- 6.5.6.1 Overview
- 6.5.6.2 Others Market Revenue and Forecast to 2027 (US$ Mn)
7. Europe Cancer Tissue Diagnostics Market Revenue And Forecasts To 2027
- 7.1 Europe Cancer Tissue Diagnostics Market Revenue And Forecasts To 2027
- 7.1.1 Europe Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
- 7.1.2 Europe Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
- 7.1.2.1 Europe Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
- 7.1.2.2 Europe In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
- 7.1.3 Europe Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Country (%)
- 7.1.4 UK Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
- 7.1.4.1 UK Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
- 7.1.4.2 UK Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
- 7.1.4.2.1 UK Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
- 7.1.4.2.2 UK In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
- 7.1.5 Germany Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
- 7.1.5.1 Germany Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
- 7.1.5.2 Germany Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
- 7.1.5.2.1 Germany Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
- 7.1.5.2.2 Germany In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
- 7.1.6 France Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
- 7.1.6.1 France Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
- 7.1.6.2 France Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
- 7.1.6.2.1 France Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
- 7.1.6.2.2 France In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
- 7.1.7 Italy Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
- 7.1.7.1 Italy Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
- 7.1.7.2 Italy Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
- 7.1.7.2.1 Italy Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
- 7.1.7.2.2 Italy In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
- 7.1.8 Spain Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
- 7.1.8.1 Spain Cancer Tissue Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
- 7.1.8.2 Spain Cancer Tissue Diagnostics Market Revenue And Forecasts to 2027, By Test Type (US$ Mn)
- 7.1.8.2.1 Spain Immunohistochemical Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
- 7.1.8.2.2 Spain In Situ Hybridization Tests Market Revenue And Forecasts to 2027, By Type (US$ Mn)
8. Cancer Tissue Diagnostics Market – Industry Landscape
- 8.1 Overview
- 8.2 Growth Strategies In The Cancer Tissue Diagnostics Market, 2016-2019
- 8.3 Organic Growth Strategies
- 8.3.1 Overview
- 8.4 Organic Growth Strategies In The Cancer Tissue Diagnostics Market, 2016-2019 (%)
- 8.4.1 Product Launches
- 8.4.1.1 Recent Product Launches By Players In The Cancer Tissue Diagnostics Market
- 8.4.2 Product Approvals
- 8.4.2.1 Recent Product Approvals By Players In The Cancer Tissue Diagnostics Market
- 8.4.3 Expansion & Other Activities
- 8.4.3.1 Recent Expansion & Other Activities By Players In The Cancer Tissue Diagnostics Market
- 8.4.4 Product Enhancements
- 8.4.4.1 Recent Product Enhancements By Players In The Cancer Tissue Diagnostics Market
- 8.4.1 Product Launches
- 8.5 Inorganic Growth Strategies
- 8.5.1 Overview
- 8.6 Inorganic Growth Strategies In The Cancer Tissue Diagnostics Market, 2016-2019 (%)
- 8.6.1 Agreements
- 8.6.1.1 Recent Agreements By Players In The Cancer Tissue Diagnostics Market
- 8.6.2 Partnerships & Collaborations
- 8.6.2.1 Recent Partnerships & Collaborations By Players In The Cancer Tissue Diagnostics Market
- 8.6.3 Acquisitions
- 8.6.3.1 Recent Acquisitions By Players In The Cancer Tissue Diagnostics Market
9. Cancer Tissue Diagnostics Market–Key Company Profiles
- 9.1 Bio-Rad Laboratories, Inc.
- 9.1.1 Key Facts
- 9.1.2 Business Description
- 9.1.3 Financial Information
- 9.1.4 Product Portfolio
- 9.1.5 SWOT Analysis
- 9.1.6 Key Developments
- 9.2 Thermo Fisher Scientific, Inc.
- 9.2.1 Key Facts
- 9.2.2 Business Description
- 9.2.3 Financial Information
- 9.2.4 Product Portfolio
- 9.2.5 SWOT Analysis
- 9.2.6 Key Developments
- 9.3 F. Hoffmann-La Roche Ltd.
- 9.3.1 Key Facts
- 9.3.2 Business Description
- 9.3.3 Financial Overview
- 9.3.4 Product Portfolio
- 9.3.5 SWOT Analysis
- 9.3.6 Key Developments
- 9.4 Abbott
- 9.4.1 Key Facts
- 9.4.2 Business Description
- 9.4.3 Financial Overview
- 9.4.4 Product Portfolio
- 9.4.5 SWOT Analysis
- 9.4.6 Key Developments
- 9.5 Enzo Biochem Inc.
- 9.5.1 Key Facts
- 9.5.2 Business Description
- 9.5.3 Financial Overview
- 9.5.4 Product Portfolio
- 9.5.5 SWOT Analysis
- 9.5.6 Key Developments
- 9.6 Agilent Technologies, Inc.
- 9.6.1 Key Facts
- 9.6.2 Business Description
- 9.6.3 Financial Overview
- 9.6.4 Product Portfolio
- 9.6.5 SWOT Analysis
- 9.6.6 Key Developments
- 9.7 Cancer Genetics Inc.
- 9.7.1 Key Facts
- 9.7.2 Business Description
- 9.7.3 Financial Overview
- 9.7.4 Product Portfolio
- 9.7.5 SWOT Analysis
- 9.7.6 Key Developments
- 9.8 Merck Kgaa (Sigma-Aldrich)
- 9.8.1 Key Facts
- 9.8.2 Business Description
- 9.8.3 Financial Overview
- 9.8.4 Product Portfolio
- 9.8.5 SWOT Analysis
- 9.8.6 Key Developments
- 9.9 Abcam Plc.
- 9.9.1 Key Facts
- 9.9.2 Business Description
- 9.9.3 Financial Overview
- 9.9.4 Product Portfolio
- 9.9.5 SWOT Analysis
- 9.9.6 Key Developments
- 9.10 Danaher
- 9.10.1 Key Facts
- 9.10.2 Business Description
- 9.10.3 Financial Information
- 9.10.4 Product Portfolio
- 9.10.5 SWOT Analysis
- 9.10.6 Key Developments
10. Appendix
- 10.1 About The Insight Partners
- 10.2 Glossary Of Terms
- 10.3 Methodology
- 10.3.1 Coverage
- 10.3.2 Secondary Research
- 8.6.1 Agreements
Summary:
Get latest Market Research Reports on Europe Cancer Tissue Diagnostics. Industry analysis & Market Report on Europe Cancer Tissue Diagnostics is a syndicated market report, published as Europe Cancer Tissue Diagnostics Market to 2027 - Regional Analysis and Forecasts by Test Type (Immunohistochemical Tests and In Situ Hybridization Tests), and Country. It is complete Research Study and Industry Analysis of Europe Cancer Tissue Diagnostics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
